Novartis receives Japanese approval for Zolgensma for spinal muscular atrophy Medical Dialogues Bureau22 March 2020 11:45 AM ISTZolgensma is a one-time gene therapy designed to address the genetic root cause of the disease by replacing the function of the missing or nonworking...
Roche anticipates USFDA nod for SMA drug Risdiplam by early 2020 Medical Dialogues Bureau26 Nov 2019 9:28 AM ISTRoche, whose drug Risdiplam is seen as a rival for Biogen's Spinraza and Novartis's Zolgensma gene therapy, said the FDA is due to decide by May 24....
Another delay in USD 2.1 million gene therapy Zolgensma data reporting, Novartis admits mistake Medical Dialogues Bureau3 Nov 2019 9:45 AM ISTThe USFDA on Wednesday placed a partial hold on a Novartis trial of the $2.1 million-per-patient gene therapy, Zolgensma after the company informed...
SETBACK: Novartis Zolgensma study halted by USFDA amid safety concerns Medical Dialogues Bureau31 Oct 2019 9:45 AM ISTNovartis shares fell 1% at 0715 GMT, while other European drugmakers rose. Analysts said more information was needed to assess whether these findings...
Novartis gets USFDA nod for over Rs 13 crore gene therapy Zolgensma Farhat Nasim25 May 2019 10:00 AM ISTThe Food and Drug Administration on Friday approved the treatment, called Zolgensma, for all children under age 2 who are confirmed by a genetic test...
Virinchi Hospitals partners with MedGenome to offer Molecular diagnostics Ruby Khatun Khatun24 Nov 2017 10:17 AM ISTHyderabad: Virinchi Hospitals, a subsidiary of Hyderabad-based IT company Virinch Limited has partnered with MedGenome, a genomics-based diagnostics...
